Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Acacia Pharma Ltd. (Cambridge, U.K.) said its lead product APD421 reduced the incidence of post-operative nausea and vomiting in two Phase III trials of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury